Literature DB >> 28495643

Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.

Hisham Abdel-Azim1, Amro Elshoury2, Kris M Mahadeo3, Robertson Parkman3, Neena Kapoor3.   

Abstract

Although T cell immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been well studied, long-term B cell immune reconstitution remains less characterized. We evaluated humoral immune reconstitution among 71 pediatric allo-HSCT recipients. Although tetanus toxoid antibody levels were normal at 1 year after allo-HSCT, antipolysaccharide carbohydrate antibodies remained persistently low for up to 5 years. While naive B cell counts normalized by 6 months, IgM memory B cell deficiency persisted for up to 2 years (P = .01); switched memory B cell deficiency normalized by 1 year after allo-HSCT. CD4+ T cell immune reconstitution correlated with that of switched memory B cells as early as 6 months after allo-HSCT (r = .55, P = .002) but did not correlate with IgM memory B cells at any time point after allo-HSCT. Taken together, this suggests that allo-HSCT recipients have impaired antibody immune reconstitution, mainly due to IgM memory B cell maturation block, compared with more prompt T cell-dependent switched memory cell immune reconstitution. We further explored other factors that might affect humoral immune reconstitution. The use of total body irradiation was associated with lower naive B cells counts at 6 months after HSCT (P = .04) and lower IgM (P = .008) and switched (P = .003) memory B cells up to 2 years. Allo-HSCT recipients with extensive chronic graft-versus-host disease had lower IgM memory B cell counts (P = .03) up to 2 years after allo-HSCT. The use of cord blood was associated with better naive (P = .01), IgM (P = .0005), and switched memory (P = .006) B cells immune reconstitution. These findings may inform future prophylaxis and treatment strategies regarding risk of overwhelming infection, graft-versus-host disease, and post-allogeneic HSCT revaccination.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic transplantation; B cell; Children; Humoral; Immune reconstitution

Mesh:

Substances:

Year:  2017        PMID: 28495643     DOI: 10.1016/j.bbmt.2017.05.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

Review 1.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

2.  Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.

Authors:  Sybille Landwehr-Kenzel; Leonie Müller-Jensen; Joern-Sven Kuehl; Mohamed Abou-El-Enein; Henrike Hoffmann; Sandra Muench; Daniel Kaiser; Andy Roemhild; Horst von Bernuth; Mirjam Voeller; Michael Schmueck-Henneresse; Bernd Gruhn; Ulrik Stervbo; Nina Babel; Hans-Dieter Volk; Petra Reinke
Journal:  Mol Ther       Date:  2022-02-28       Impact factor: 12.910

3.  Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation.

Authors:  Rachel A Bender Ignacio; Sayan Dasgupta; Terry Stevens-Ayers; Tomasz Kula; Joshua A Hill; Stephanie J Lee; Marco Mielcarek; Ann Duerr; Stephen J Elledge; Michael Boeckh
Journal:  Blood       Date:  2019-06-11       Impact factor: 25.476

4.  A Controlled Trial of Sheng-Yu-Tang for Post-Hematopoietic Stem Cell Transplantation Leukemia Patients: A Proposed Protocol and Insights From a Preliminary Pilot Study.

Authors:  Tom Fleischer; Tung-Ti Chang; Jen-Huai Chiang; Hung-Rong Yen
Journal:  Integr Cancer Ther       Date:  2018-02-11       Impact factor: 3.279

Review 5.  B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children.

Authors:  Nicolaas G van der Maas; Dagmar Berghuis; Mirjam van der Burg; Arjan C Lankester
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

6.  Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation.

Authors:  Julia Winkler; Hannes Tittlbach; Andrea Schneider; Corinna Buchstaller; Andreas Mayr; Ingrid Vasova; Wolf Roesler; Michael Mach; Andreas Mackensen; Thomas H Winkler
Journal:  Ann Hematol       Date:  2020-06-09       Impact factor: 3.673

Review 7.  Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.

Authors:  Sima T Bhatt; Jeffrey J Bednarski
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

8.  National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.

Authors:  Anita Lawitschka; Ece Dila Gueclue; Angela Januszko; Ulrike Körmöczi; Arno Rottal; Gerhard Fritsch; Dorothea Bauer; Christina Peters; Hildegard T Greinix; Winfried F Pickl; Zoya Kuzmina
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

9.  "My son can not attend the school because 5 classmates are unvaccinated". On the question of compulsory vaccinations and the risk for immune-compromised children into the schools: the case of paediatric cancer patients.

Authors:  Silvana Acquafredda; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2018-11-05       Impact factor: 3.452

Review 10.  Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.

Authors:  Katayoun Rezvani; Sattva S Neelapu; Elizabeth J Shpall; Kris M Mahadeo; Sajad J Khazal; Hisham Abdel-Azim; Julie C Fitzgerald; Agne Taraseviciute; Catherine M Bollard; Priti Tewari; Christine Duncan; Chani Traube; David McCall; Marie E Steiner; Ira M Cheifetz; Leslie E Lehmann; Rodrigo Mejia; John M Slopis; Rajinder Bajwa; Partow Kebriaei; Paul L Martin; Jerelyn Moffet; Jennifer McArthur; Demetrios Petropoulos; Joan O'Hanlon Curry; Sarah Featherston; Jessica Foglesong; Basirat Shoberu; Alison Gulbis; Maria E Mireles; Lisa Hafemeister; Cathy Nguyen; Neena Kapoor
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.